PATH-HHT, a Double-Blind, Randomized, Placebo-Controlled Trial in Hereditary Hemorrhagic Telangiectasia Demonstrates That Pomalidomide Reduces Epistaxis and Improves Quality of Life

Published on December 14, 2023

Late Breaking Abstract: PATH-HHT STUDY

 

Click above to read the late-breaking abstract submission to the American Society of Hematology Conference in December 2023. This abstract was featured as an oral presentation and details the outcomes of the recently concluded NIH-supported clinical trial 'Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)'. 

 

Find more information on the trial here. 

Other news

Who Runs the World? Highlighting Research on Women and Girls With Bleeding Disorders - HHT in the News

December 14, 2023
Abstract featuring HHT pulled into ASH Daily News article highlighting women and girls with bleeding disorders Who Runs the World? Highlighting Research on Women and Girls with Bleeding Disorders Ellen Zhang, MD from Stanford, in collaboration with Vanderbilt University and Mass General Hospital, presented work analyzing the impact of inherited bleeding disorders HHT and VWS on women to determine

The University of Pittsburgh’s Dr. Anthony Anzell Presented with $20,000 Research Grant from Uplifting Athletes

January 12, 2024
The University of Pittsburgh’s Dr. Anthony Anzell Presented with $20,000 Research Grant from Uplifting AthletesDr. Anzell is among 10 rare disease researchers to be awarded a grant at Uplifting Athletes’ Young Investigator Draft on Feb. 3 at Lincoln Financial Field Pittsburgh (January 9, 2024) — Uplifting Athletes, a nonprofit organization dedicated to serving the rare disease community, has annou